Verastem(NASDAQ) VSTM

Verastem, Inc. makes medicines to treat difficult types of cancer. These drugs help patients whose current treatments no longer work. The company blocks signals that help tumors grow and survive.

Fighting Cancer With Precision Tools

• AVMAPKI FAKZYNJA CO-PACK: Treatment for adults with recurrent low-grade serous ovarian cancer; consists of a combination of capsules and tablets.
• Avutometinib: Oral medicine designed to block specific proteins that allow cancer cells to multiply and grow.
• Defactinib: Small molecule drug that stops a pathway tumors use to resist treatment; often paired with other therapies.
• VS-7375: Experimental treatment for solid tumors in the lungs, pancreas, and colon; currently undergoing multiple clinical trials.

Expanding the Research Pipeline

• Launched the first commercial sale of AVMAPKI FAKZYNJA CO-PACK in the United States in May 2025.
• Started three new Phase 2 clinical trials for VS-7375 in June 2026.
• Obtained Fast Track Designation from the FDA for lung cancer treatment in June 2026.
• Partnered with Erasca in July 2026 to evaluate combining different cancer medications in preclinical studies.

Why These Treatments Stand Out

Verastem uses a unique clamp mechanism to block cancer signaling pathways while simultaneously preventing the tumor from building drug resistance. The company maintains strategic partnerships with global pharmaceutical firms like Pfizer and Amgen to explore combined therapies for various cancer mutations.

Financial Results and Funding Status

• Net product revenue reached $25.1 million in the three months ended June 30, 2026, up 1074% year over year.
• Research and development expenses rose 67% year over year to $41.3 million during the three months ended June 30, 2026.
• Cash, cash equivalents, and investments totaled $136.4 million as of June 30, 2026.
• Rising research costs raised substantial doubt about the company's ability to continue as a going concern within 12 months.

Bottom Line

Verastem has evolved from a research-focused organization to a commercial-stage business with the launch of its first FDA-approved treatment. It is now focused on expanding its product reach and advancing a pipeline of experimental drugs for difficult-to-treat cancers.